Yijia Li (@yijiali89) Bsky

Still waiting... alas

1 day ago 0 0 0 0

Refection after the rain

5 days ago 1 0 0 0

Second Venezuelan Doctor Detained in South Texas by Immigration Agents

This is the second case. Another physician who followed the legal immigration process, who works in the US serving undeserved communities detained by ICE. This is not about removing criminals it's about purging non White immigrants even those doing valuable service!
www.nytimes.com/2026/04/11/u...

1 week ago 340 155 2 4

2 weeks ago 2 0 0 0

Omg this is gold 😂

2 weeks ago 0 0 0 0

Tufted Titmouse (Baeolophus bicolor). Photo © Enrique Shore
#bird #birds #nature #birding #feathers

2 weeks ago 1155 85 15 1

Review @cellcellpress.bsky.social @lowelab.bsky.social @mskcancercenter.bsky.social
Senescence in cancer: Hallmarks, paradoxes, and therapeutic promise
www.cell.com/cell/fulltex...

2 weeks ago 2 1 0 0

My baby

2 weeks ago 0 0 0 0

Long-term outcomes of chronic active Epstein-Barr virus infection in childhood after dominantly infected lymphocyte subpopulation management Chronic active Epstein-Barr virus (EBV) disease (CAEBV) is an uncommon lethal infection involving EBV-infected T and/or NK-cells, often complicated by hemophagocytic lymphohistiocytosis (HLH). Patients need curative hematopoietic cell transplantation (HCT), but the indication and timing remain unclear. This study aimed to assess the prognostic value of EBV-infected lymphocyte subsets.MethodsWe analyzed 52 pediatric/young-adult patients diagnosed with persistently EBV infection from 2003 to 2025 at a single tertiary center in Japan, excluding acute infectious mononucleosis and secondary immunodeficiencies. Dominant EBV-infected cell types (CD4+, CD8+, γδT-cells, CD19+B-cells, and CD56+NK-cells) were determined at diagnosis of CAEBV (n = 21), EBV-HLH (n = 19), or inborn errors of immunity (IEI, n = 12). The long-term outcomes were analyzed by major infected cell types and treatment.ResultsCAEBV included 12 T-cell (6 CD4+, 4 CD8+, and 2 γδ) and 9 NK-cell dominant infections. EBV-HLH and IEI exclusively involved CD8+T-cell and B-cell infections, respectively. Thirteen CAEBV patients (62%) underwent HCT to control progression including 5 patients who presented with HLH. The 3-year overall survival (OS) was 88%, although CD4+T-cell disease (all CAEBV) showed a significantly lower survival rate. Posttransplant deaths occurred in 3 of 13 CAEBV and none of EBV-HLH patients. Among 9 CAEBV patients with median 11-year progression-free survival without HCT, each one of CD4+T-cell or NK-cell case transformed to lymphoma or leukemia after being untreated for >10 years.ConclusionsEBV-infected lymphocyte profiling guided prolonged HCT-free control of CAEBV. CD4+T-cell CAEBV requires a prompt rather than elective HCT to prevent progression and transformation.

CAEBV pts (n=21) had 62% HCT; 3-yr OS 88%. CD4+T-cell CAEBV had lower survival, needing prompt HCT. Untreated >10yrs, 2 pts got lymphoma/leukemia. EBV-infected cell type is key. ⚠️🦠

3 weeks ago 0 1 0 0

An emerging human eye disease is associated with aquatic virus zoonotic infection - Nature Microbiology Covert mortality nodavirus, a pathogen previously known to cause important losses in shrimp aquaculture, is identified as being a potential causative agent of an emerging and severe ocular disease in ...

A new study in Nature Microbiology reveals that an eye condition called POH-VAU (persistent ocular hypertensive viral anterior uveitis) is caused by covert mortality nodavirus (CMNV) - a virus that's been devastating shrimp farms for over a decade.
www.nature.com/articles/s41...

3 weeks ago 40 18 1 2

@sebpoule.bsky.social

3 weeks ago 1 0 0 0

A systematic review and meta-analysis of hepatitis B virus drug resistance and escape mutations in low- and middle-income countries :Hepatitis B virus (HBV) remains highly endemic in many low- and middle-income countries (LMICs), where challenges such as antiviral resistance and immune/vaccine-escape mutations complicate disease management.Objective:This review synthesizes current data on HBV drug resistance, including the prevalence and distribution of resistance-associated mutations (RAMs), vaccine-escape mutations (VEMs), and immune-escape mutations (IEMs) in LMICs.Design:Systematic review and meta-analysis.Data sources:PubMed, Scopus, and Web of Science.Methods:A systematic search was conducted from 2014 to 2025 (last search date: August 04, 2025), and data were extracted from eligible studies. A random-effects meta-analysis was conducted to estimate pooled resistance rates and prevalences.Results:A total of 43,834 participants from 47 studies conducted in 28 LMICs were included. The overall antiviral resistance rate was 7.87% (95% CI (5.13–11.11)), with very high heterogeneity (I2 = 99.7%). Lamivudine (3TC) and telbivudine (LdT) had the highest resistance rates. Asia consistently reported the greatest resistance, with rates of 32.45% for 3TC and 51.92% for LdT. In a subgroup analysis on economic regions, Lower-middle-income countries showed the highest pooled resistance rate at 10.61% (95% CI (5.21–17.51); I2 = 96.9%). The most frequently detected RAMs were rtM204V/I, rtV173L, and rtL180M. The pooled prevalence of vaccine-escape mutations was 8.92% (95% CI (5.02–13.64); I2 = 78.4%). Immune-escape mutations were much more common, with a pooled prevalence of 55.66% (95% CI (28.10–81.53); I2 = 98.1%). The most prevalent mutations were sG145R/A/K, sQ129H/R, sD144E/A, sS143L/T, and sP120S/T. The pooled estimates in this study are reported and interpreted descriptively, given the substantial heterogeneity observed.Conclusion:The remarkably high drug resistance rates and prevalence of immune and vaccine-escape mutations suggest notable burdens of resistance, especially for drugs with low genetic barriers such as lamivudine and telbivudine, underscoring the growing challenges in achieving the WHO 2030 reduction goals, and highlighting the need for enhanced surveillance, adoption of potent antiviral regimens such as tenofovir disoproxil fumarate, and continuous vaccine efficacy monitoring. However, the results should be interpreted with caution due to the very high heterogeneity observed in the study.Trial registration:International prospective register of systematic reviews (PROSPERO) under the ID: CRD420251030302.

HBV drug resistance in 28 LMICs: 7.87%🦠, highest in Asia (3TC 32.45%, LdT 51.92%). Vaccine-escape 8.92%, immune-escape 55.66%. Highlights need for better antivirals & surveillance.

3 weeks ago 0 1 0 1

3 weeks ago 0 0 0 0

They think they are god, perhaps.

3 weeks ago 1 0 0 0

Stoat hopping across snow: #AGoodPlace

Source: www.reddit.com/r/NatureIsFu...

3 weeks ago 2579 411 78 40

Hookworm vaccine

www.thelancet.com/journals/lan...

1 month ago 243 58 4 7

potato

1 month ago 2 0 0 0

1 month ago 1 0 0 0

Oh she leaving again?! Bye gurl never come back….

1 month ago 2 0 1 0

Autoantibdoy signature in patients with autoimmune hepatitis show cross-reactivity with human herpesvirus 6 and the antifibrotic relaxin receptor with potential to promote fibrosis progression @jem.org
rupress.org/jem/article/...

1 month ago 3 1 0 0

Since when mabs are named xxx-bart... it sounds like dog food...

1 month ago 1 0 0 0

Meow meow meow meow

1 month ago 0 0 0 0

Missed my baby!

1 month ago 0 0 0 0

Integrase anchors viral RNA to the HIV-1 capsid interior - Nature HIV-1 integrase forms an RNA-binding module on the luminal side of the mature capsid lattice.

Nature research paper: Integrase anchors viral RNA to the HIV-1 capsid interior

go.nature.com/3OlzcfC

1 month ago 11 2 0 0

Seriously same question….

2 months ago 1 0 0 0

FDA reverses course, agrees to review Moderna’s flu vaccine The FDA reversed course and told Moderna it would review its application for a new flu vaccine, the company announced Wednesday.

Unclear to me what accounts for this change, but I suppose it's good news:

www.statnews.com/2026/02/18/f...

2 months ago 229 53 11 6

Wait this is not SNL?!

2 months ago 2 0 0 0

[Obviously I'm being sarcastic. This was where we were headed from the moment he picked his HHS Secretary] Vaccine Makers Pull Back on Investment and Innovation Amid Trump Policies The Trump administration's dismantling of longstanding federal support for vaccines has "sent a chill through the entire industry," one scientist said.

No one could've seen this coming... 🙄

www.nytimes.com/2026/02/16/h...

2 months ago 116 37 2 3

Posts by Yijia Li